PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Clinical trial NCT06533384 · RECRUITING

Trial details

NCT number: NCT06533384
Sponsor: Guangdong Provincial People's Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple-negative Breast Cancer

Start date: 2024-08-01
Primary completion: 2026-12-31
Enrollment: 310

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.